Neurocrine Biosciences, Inc.
NBIX
$118.78
$1.911.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 305.80M | 341.30M | 385.90M | 339.20M | 369.70M |
| Total Depreciation and Amortization | 28.50M | 27.10M | 25.70M | 24.70M | 22.50M |
| Total Amortization of Deferred Charges | -88.70M | 0.00 | 0.00 | 138.40M | 88.70M |
| Total Other Non-Cash Items | 295.60M | 246.20M | 232.00M | 153.70M | 110.40M |
| Change in Net Operating Assets | -11.30M | -19.20M | -167.20M | -125.60M | 54.10M |
| Cash from Operations | 529.90M | 595.40M | 476.40M | 530.40M | 645.40M |
| Capital Expenditure | -37.70M | -38.20M | -36.30M | -35.80M | -31.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -19.90M | -88.60M | -224.00M | -346.50M | -449.00M |
| Cash from Investing | -57.60M | -126.80M | -260.30M | -382.30M | -480.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -308.80M | -308.80M | -308.80M | -308.80M | -- |
| Issuance of Common Stock | 84.30M | 122.10M | 147.50M | 139.90M | 127.00M |
| Repurchase of Common Stock | -450.00M | -300.00M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -674.50M | -486.70M | -161.30M | -168.90M | 127.00M |
| Foreign Exchange rate Adjustments | 0.00 | 0.00 | 600.00K | 300.00K | 300.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -202.20M | -18.10M | 55.40M | -20.50M | 292.70M |